Vor Biopharma
68 hedge funds and large institutions have $140M invested in Vor Biopharma in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 2 closing their positions.
3,700% more call options, than puts
Call options by funds: $38K | Put options by funds: $1K
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
13% more funds holding
Funds holding: 60 → 68 (+8)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
1.42% less ownership
Funds ownership: 87.9% → 86.47% (-1.4%)
35% less capital inflows, than outflows
Capital inflows: $2.25M | Capital outflows: $3.48M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$621K |
| 2 |
Millennium Management
New York
|
+$348K |
| 3 |
Exchange Traded Concepts
Oklahoma City,
Oklahoma
|
+$207K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$168K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.96M |
| 2 |
Morgan Stanley
New York
|
-$100K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$81.2K |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$65.9K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$54.7K |
VOR Hedge Fund Activity: Q1 2024 in Review
68 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2024, worth a combined $140M — up 4.2% from $134M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VOR positions and 2 closed out — a net gain of 9 holders — while 19 added to existing stakes and 20 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $621K. The largest seller was Artal Group, cutting an estimated $2.96M.
- 68 institutional investors held Vor Biopharma (VOR) as of Q1 2024, up from 60 in Q4 2023.
- Funds reported $140M of Vor Biopharma stock for Q1 2024, up 4.2% quarter-over-quarter.
- 11 funds opened new Vor Biopharma positions in Q1 2024 and 2 closed out, a net change of +9 holders.
- The largest Vor Biopharma buyer in Q1 2024 was Renaissance Technologies, an estimated $621K added.
- The largest Vor Biopharma seller in Q1 2024 was Artal Group, an estimated $2.96M sold.
Based on aggregated 13F filings for Q1 2024.